Evidence map›Paper›PMID 37609311›Full record

ArticlemedRxiv : the preprint server for health sciences2023

Noninvasive molecular subtyping of pediatric low-grade glioma with self-supervised transfer learning.

Divyanshu Tak, Zezhong Ye, Anna Zapaishchykova, Yining Zha, Aidan Boyd, Sridhar Vajapeyam, Rishi Chopra, Hasaan Hayat, Sanjay Prabhu, Kevin X Liu and 11 more

Open access · greenAbstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 5 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 4 institutions in 2 countries.

Divyanshu TakArtificial Intelligence in Medicine (AIM) Program, Mass General Brigham, Harvard Medical School, Boston, MA, USA.
Zezhong YeArtificial Intelligence in Medicine (AIM) Program, Mass General Brigham, Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-0369-7432
Anna ZapaishchykovaArtificial Intelligence in Medicine (AIM) Program, Mass General Brigham, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-6860-9160
Yining ZhaArtificial Intelligence in Medicine (AIM) Program, Mass General Brigham, Harvard Medical School, Boston, MA, USA.
Aidan BoydArtificial Intelligence in Medicine (AIM) Program, Mass General Brigham, Harvard Medical School, Boston, MA, USA.
Sridhar VajapeyamDepartment of Radiology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Rishi ChopraArtificial Intelligence in Medicine (AIM) Program, Mass General Brigham, Harvard Medical School, Boston, MA, USA.
Hasaan HayatArtificial Intelligence in Medicine (AIM) Program, Mass General Brigham, Harvard Medical School, Boston, MA, USA.
Sanjay PrabhuDepartment of Radiology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-0871-115X
Kevin X LiuDepartment of Radiation Oncology, Dana-Farber Cancer Institute | Brigham and Women's Hospital | Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Hesham ElhalawaniDepartment of Radiation Oncology, Dana-Farber Cancer Institute | Brigham and Women's Hospital | Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Ali NabavizadehCenter for Data-Driven Discovery in Biomedicine (D3b), Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Ariana FamiliarCenter for Data-Driven Discovery in Biomedicine (D3b), Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Adam ResnickDepartment of Neurosurgery, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Sabine MuellerDepartment of Neurology, University of California San Francisco, San Francisco, CA. USA.
Hugo J W L AertsArtificial Intelligence in Medicine (AIM) Program, Mass General Brigham, Harvard Medical School, Boston, MA, USA.
Pratiti BandopadhayayDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Keith LigonDepartment of Pathology, Dana-Farber Cancer Institute, Boston Children's Hospital, Harvard Medical School, Boston, A, USA.
Daphne Haas-KoganDepartment of Radiation Oncology, Dana-Farber Cancer Institute | Brigham and Women's Hospital | Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Tina PoussaintDepartment of Radiology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Benjamin H KannArtificial Intelligence in Medicine (AIM) Program, Mass General Brigham, Harvard Medical School, Boston, MA, USA.
Brigham and Women's Hospital · USBoston Children's Hospital · USChildren's Hospital of Philadelphia · USUniversity of California, San Francisco · US

Funding

Targeting the Vasular SystemP50CA165962 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Benjamin Harris Kann · 2013 to 2026
$33.5M
The Boston Lung Cancer Survival CohortU01CA209414 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI David C Christiani · 2017 to 2026
$12.2M
Quantitative Radiomics System Decoding the Tumor PhenotypeU24CA194354 · NCI · DANA-FARBER CANCER INST · PI AERTS, HUGO, QUACKENBUSH, JOHN · 2015 to 2019
$3.5M
Genotype and Imaging Phenotype Biomarkers in Lung CancerU01CA190234 · NCI · DANA-FARBER CANCER INST · PI AERTS, HUGO, QUACKENBUSH, JOHN · 2015 to 2019
$3.3M
Development of an artificial intelligence-driven, imaging-based platform for pretreatment identification of extranodal extension in head and neck cancerK08DE030216 · NIDCR · BRIGHAM AND WOMEN'S HOSPITAL · PI KANN, BENJAMIN HARRIS · 2021 to 2025
$841k
NCI NIH HHS P50 CA165962NCI NIH HHS U01 CA190234NCI NIH HHS U01 CA209414NCI NIH HHS U24 CA194354NIDCR NIH HHS K08 DE030216
6 · The paper itself

Abstract

Purpose: To develop and externally validate a scan-to-prediction deep-learning pipeline for noninvasive, MRI-based BRAF mutational status classification for pLGG. Materials and Methods: We conducted a retrospective study of two pLGG datasets with linked genomic and diagnostic T2-weighted MRI of patients: BCH (development dataset, n=214 [60 (28%) BRAF fusion, 50 (23%) BRAF V600E, 104 (49%) wild-type), and Child Brain Tumor Network (CBTN) (external validation, n=112 [60 (53%) BRAF-Fusion, 17 (15%) BRAF-V600E, 35 (32%) wild-type]). We developed a deep learning pipeline to classify BRAF mutational status (V600E vs. fusion vs. wildtype) via a two-stage process: 1) 3D tumor segmentation and extraction of axial tumor images, and 2) slice-wise, deep learning-based classification of mutational status. We investigated knowledge-transfer and self-supervised approaches to prevent model overfitting with a primary endpoint of the area under the receiver operating characteristic curve (AUC). To enhance model interpretability, we developed a novel metric, COMDist, that quantifies the accuracy of model attention around the tumor. Results: A combination of transfer learning from a pretrained medical imaging-specific network and self-supervised label cross-training (TransferX) coupled with consensus logic yielded the highest macro-average AUC (0.82 [95% CI: 0.70-0.90]) and accuracy (77%) on internal validation, with an AUC improvement of +17.7% and a COMDist improvement of +6.4% versus training from scratch. On external validation, the TransferX model yielded AUC (0.73 [95% CI 0.68-0.88]) and accuracy (75%). Conclusion: Transfer learning and self-supervised cross-training improved classification performance and generalizability for noninvasive pLGG mutational status prediction in a limited data scenario.

Identifiers

PMID37609311
PMCPMC10441478
OpenAlexW4385650286

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.